<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094090</url>
  </required_header>
  <id_info>
    <org_study_id>PXL-2211</org_study_id>
    <nct_id>NCT04094090</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goodman Eye Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goodman Eye Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the PXL Platinum 330 system for performing
      corneal cross-linking (CXL) for the treatment of ectatic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,
      visual acuity, intraocular pressure, pachymetry, and visual function questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2029</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>change in corrected distance visual acuity (CDVA) at the last required study visit (6 months post-op), compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Change in UCVA at 6 months, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Keratometry</measure>
    <time_frame>1 year</time_frame>
    <description>Change in Kmax, compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Keratoconus</condition>
  <condition>Pellucid Marginal Corneal Degeneration</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mW, 10 sec on, 10 sec off, 22.5 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pusled, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mW, 10 sec on, 10 sec off, 11.25 minutes of illumination Intervention: Combination Product: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution</intervention_name>
    <description>Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea</description>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_label>Pusled, accelerated</arm_group_label>
    <other_name>Corneal crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who have one or both eyes that meet criteria 1 and 1 or more of the following
        criteria will be considered candidates for this study:

        1.10 years of age or older 2. Presence of central or inferior steepening 3. Axial
        topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal
        degeneration 4. Presence of one or more findings associated with keratoconus or pellucid
        marginal degeneration, such as:

          1. Fleischer ring

          2. Vogt's striae

          3. Decentered corneal apex

          4. Munson's sign

          5. Apical Corneal scarring consistent with Bowman's breaks

          6. Scissoring of the retinoscopic reflex

          7. Crab-claw appearance on topography 5. Steepest keratometry (Kmax) value â‰¥ 47.20 D 6.
             I-S keratometry difference &gt; 1.5 D on the Pentacam map or topography map 7. Posterior
             corneal elevation &gt;16 microns 8. Thinnest corneal point &gt;300 microns 9. Contact Lens
             Wearers Only:

        a. Removal of contact lenses for the required period of time prior to the screening
        refraction: Contact Lens Type Minimum Discontinuation Time Soft or Scleral 3 days Rigid gas
        permeable 2 weeks

        Exclusion Criteria:

        All subjects meeting any of the following criteria will be excluded from this study:

          1. Eyes classified as either normal or atypical normal on the severity grading scheme.

          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the thinnest point in
             the eye(s) to be treated.

          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated
             that may predispose the eye for future complications, for example:

               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster
                  keratitis, recurrent erosion syndrome, acanthomeoeba, etc.)

               2. Clinically significant corneal scarring in the CXL treatment zone that is not
                  related to keratoconus or, in the investigator's opinion, will interfere with the
                  cross-linking procedure.

          4. Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          5. A known sensitivity to study medications

          6. Patients with nystagmus or any other condition that would prevent a steady gaze during
             the CXL treatment or other diagnostic tests.

          7. Patients with a current condition that, in the physician's opinion, would interfere
             with or prolong epithelial healing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Goodman Eye Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel F Goodman, MD</last_name>
      <phone>415-474-3333</phone>
      <email>swong@goodmaneyecenter.com</email>
    </contact>
    <investigator>
      <last_name>Daniel F Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will be held in a secure location. While summary outcomes data will be provided on request to other researchers and periodically at scientific conferences, protected health information will not.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04094090/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

